Opus Genetics, Inc. Cash and Restricted Cash
Opus Genetics, Inc. (IRD) had Cash and Restricted Cash of $88.91 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $88.91M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59.96M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45.09M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $30.82M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $88.91M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $59.96M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $45.09M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $30.82M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $32.43M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $41.79M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $30.32M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $36.63M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $41.41M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $47.16M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $50.50M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $42.35M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $39.98M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $38.99M 10-Q · filed 2024-05-10 | |
| 2022-12-31 | $42.63M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $13.86M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $17.02M 10-Q · filed 2023-08-11 | |
| 2022-03-31 | $19.25M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $24.53M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $22.25M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $24.23M 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $10.60M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $16.40M 10-K · filed 2023-03-30 | |
| 2020-09-30 | $722.00K 10-Q · filed 2021-11-12 | $8.08M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $854.00K 10-Q · filed 2021-08-12 | $9.21M 10-Q · filed 2020-08-14 |
| 2020-03-31 | $1.25M 10-Q · filed 2021-05-07 | $11.00M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.54M 10-K · filed 2022-03-24 | $9.22M 10-K · filed 2020-02-21 |
| 2019-09-30 | $7.93M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $7.31M 10-Q · filed 2020-08-14 | |
| 2019-03-31 | $6.12M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $451.00K 10-K · filed 2021-03-11 | $8.74M 10-Q · filed 2019-05-10 |
| 2018-09-30 | $4.59M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $5.09M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $6.30M 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $8.90M 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |